Biography:

Mark Punyanitya is a Biomedical Engineer with advanced degrees in Applied Physiology and Applied Clinical Trials. He facilitates translation of science, technology and medicine for development and commercialization of medical technologies. He is the Co-Founder, President and CEO of PhenoMx, Inc., focused on commercializing a personalized digital physical examination for precision medicine, personalized wellness and human longevity. He is also the Founder, President and CEO of Image Reading Center, Inc., Imaging Core Laboratory & CRO developing imaging biomarkers for global multi-center clinical trials. With more than 20 years implementing and standardizing medical imaging, he has more than 40 publications to his credit and his advances in imaging have been applied to a wide range of therapeutic areas.

Abstract:

The time has come where imaging biomarkers are gaining acceptance beyond tumor quantification for oncology. This session cover the creation of a Digital Physical Examination to directly measure major vital organs and tissues from a whole body perspective, based on non-invasive imaging for a wide range of conditions and diseases beyond oncology. With increasing focus on genomic, metabolomic and molecular quantification of the human body for use in precision medicine, the development of diagnostics, therapeutics and monitoring of disease progression/treatment takes on a greater role for more effective outcomes. The majority of advances have not included the phenotype or observable characteristics of an individual resulting from the interaction of its genotype with the environment. Biomarkers provide researchers and clinicians with useful measurements that allow for earlier diagnosis before a patient begins to show signs of symptoms and also quantitatively show that a treatment is performing effectively. Technology is now available to measure multiple vital organs and tissues for an integrated exam using non-invasive imaging to acquire data, automation algorithms to quantify images and AI to develop predictive analytics. A Software-as-a-Service platform enables scalable access to the latest imaging technology and support for legacy scanners, while improving accuracy, precision and standardization across imaging facilities.

Biography:

Michael J Sinosich established the Division of Prenatal Testing within Sonic Clinical Institute in 2002. Michael is an internationally respected investigator in early pregnancy well-being. He has published extensively in peer reviewed journals and presented numerous papers at local, national and international forums.

Abstract:

Biography:

Ewa Kurowska is an Obstetrics and Gynecology Consultant in Medicover Hospital, Warsaw, Poland. She is the Head Doctor of Obstetrics and Gynecology Department.

Abstract:

Cardiac arrhythmia during the pregnancy is although the risk factor is well described but is still a huge problem, because it influences two persons, mother and the fetus. The incidence of these events is estimated at 1, 2 per 1000 and 50% of them are asymptomatic. The treatment might be not needed with mild symptoms, but in some cases pharmacotherapy as a compromise between potential benefits and adverse effect on the fetus is not successful, especially in life-threatened situations. We would like to present a case of healthy women, who underwent cardio version in her second pregnancy and two in her third, all of them effective but had to have cesarean section as the result of third incident of atrial fibrillation in the last pregnancy. Although the risk factors of cardiac arrhythmia are well described, it is still the big concern how to point out and successfully manage with the pregnant women. This multidisciplinary problem demands perfect cooperation of many specialists, obstetrician, cardiologists and neonatologists with instant access to the operating theatre. Hemodynamically significant arrhythmia treated with electric cardio version seems to be safe treatment option during pregnancy. Limited data based on case reports and clinical experiences needs to be confirmed with further investigations on bigger groups of patients.

Biography:

Michael J Sinosich established the Division of Prenatal Testing within Sonic Clinical Institute in 2002. Michael is an internationally respected investigator in early pregnancy well-being. He has published extensively in peer reviewed journals and presented numerous papers at local, national and international forums.

Abstract:

Prenatal screening for assessment of fetal development has been established for almost half a century. Our first trimester screening program includes four (4) biochemical markers: PAPP-A, FhCG, PlGF and AFP. Markers were quantified (DELFIA® DXpress; PerkinElmer) and marker MoM values calculated (LifeCycle v2.2; Perkin Elmer), using lot specific derived polynomial regression curves. Pregnancies with known outcomes included: (1) Aneuploid: Trisomy 21, Trisomy 18, Trisomy 13, Triploid, Sex chromosome aneuploidies, (2) Failed pregnancies, (3) Fetal structure: Anencephaly, Fetal growth restriction, and (4) Maternal Health: Gestational trophoblastic disease, Sub-chorionic bleeding. Reduced circulating PAPP-A level is cause for concern. Low PAPP-A level is associated with aneuploidy (Trisomy/13/18/21, Triploidy) and poor pregnancy prognosis. Similarly, a low FbhCG level is also associated with compromised pregnancy. However, an elevated FbhCG is indicative of Trisomy 21. Excessively elevated FbhCG, even in presence of normal PAPP-A levels, warrants further investigation of trophoblast cell physiology. Elevated levels of fetal derived marker (AFP) may indicate increased transplacental exchange or presence of fetal structural abnormality. Biochemical profile of viable aneuploidies such as, sex chromosome aneuploidies are not distinguishable from profiles of normal pregnancies. However, NT measurements in such pregnancies are markedly increased and may present as a cystic hygroma. PlGF, a marker of placental angiogenesis, levels are reduced in first trimester pregnancies which subsequently develop early onset pre-eclampsia and/or reduced fetal development. Whilst the combination of feto-placental derived biochemistry with ultrasonographic biometry, improves Trisomy 21 detection (to about 92-93%), the inclusion of PlGF has introduced another dimension to screening because now we can simultaneously screen for both fetal and maternal wellbeing. Over the past two decades, non-invasive prenatal screening has progressed from screening for targeted fetal abnormalities to combined prenatal assessment of feto-maternal wellbeing. Each screening modality (biochemistry, ultrasonography, cfDNA) offers benefits only attained in a holistic screening offering.